Xenon Pharmaceuticals Inc.
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
Previously recorded as Xenon Genetics Inc. (to 2004)
3
Ending by 2030
May 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Oct 16, 2027The maintenance fee for Methods and Uses for Treating Anhedonia (US 11,957,675) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,293,911 | Derivatives of 4-(N-AZACYCLOALKYL) Anilides as Potassium Channel Modulators In force · Medium confidence | In force | Medium confidence | |
| US 7,700,641 | Spiro-oxindole compounds and their uses as therapeutic agents In force · From the USPTO record | In force | From the USPTO record | |
| US 8,993,593 | N-(4-(6-Fluoro-3,4-Dihydroisoquinolin-2(1H)-YL)-2,6-Dimethylphenyl)-3,3-Dimethylbutanamide as Potassium Channel Modulators In force · Medium confidence | In force | Medium confidence | |
| US 10,787,446 | Therapeutic Compounds and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,246,453 | Benzenesulfonamide compounds and their use as therapeutic agents In force · From the USPTO record | In force | From the USPTO record | |
| US 10,662,184 | Benzenesulfonamide compounds and their use as therapeutic agents In force · From the USPTO record | In force | From the USPTO record | |
| US 10,815,229 | Benzenesulfonamide compounds and their use as therapeutic agents In force · From the USPTO record | In force | From the USPTO record | |
| US 11,174,268 | Benzenesulfonamide Compounds and Their Use as Therapeutic Agents In force · High confidence | In force | High confidence | |
| US 11,299,490 | Benzenesulfonamide compounds and their use as therapeutic agents In force · From the USPTO record | In force | From the USPTO record | |
| US 11,135,214 | Methods for Enhancing the Bioavailability and Exposure of a Voltage-Gated Potassium Channel Opener In force · High confidence | In force | High confidence |
Also on record, not counted in the 23: 7 patents in force now held by others · 86 lapsed for an unpaid fee · 7 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
11 pending · 25 abandoned · 26 no status recorded